Mutant Ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 733-741

  Salloum, Darin ^a   Mukhopadhyay, Suman ^a   Tung, Kaity ^a   Polonetskaya, Aleksandra ^a   Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; RAS PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LETHALITY; LIPID BLOOD LEVEL; PHENOTYPE; PINOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; LIPIDS; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; MUTATION; RAS PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84896278325     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0762     Document Type: Article

References (26)

1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012;21:297-308.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
4. Foster DA. Phosphatidic acid and lipid-sensing by mTOR. Trends Endocrinol Metab 2013;24:272-8.
5. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010;29:313-24.
6. Das UN. Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2011;30:311-24.
7. Cheong H, Lu C, Lindsten T, Thompson CB. Therapeutic targets in cancer cell metabolismand autophagy. Nat Biotechnol 2012;30:671-8.
8. Hamanaka RB, Chandel NS. Targeting glucose metabolismfor cancer therapy. J Exp Med 2012;209:211-5.
9. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77. (Pubitemid 47469806)
10. Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 2011;189:1177-201.
11. Zheng Y, Rodrik V, Toschi A, Shi M, Hui L, Shen Y, et al. Phospholipase D couples survival and migration signals in stress response of human cancer cells. J Biol Chem 2006;281:15862-8. (Pubitemid 43848477)
12. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011;10:3948-56.
13. Gadir N, Jackson DN, Lee E, Foster DA. Defective TGF-β signaling sensitizes human cancer cells to rapamycin. Oncogene 2008;27: 1055-62. (Pubitemid 351253184)
14. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009;8:3112-9.
15. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009;29:1411-20.
16. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001;294:1942-5. (Pubitemid 33101594)
17. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009;21:209-18.
18. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging 2011;3:1130-41.
19. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA. Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS ONE 2013;8:e74157.
20. Yellen P, Chatterjee A, Preda A, Foster DA. Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest. Cancer Lett 2013;333:239-43.
21. Chen YJ, Zheng YF, Wang NF, Lu S, Pang T, Yang Q, et al. Significance of urinary nucleosides in diagnosis of gastric carcinoma. Ai Zheng 2003;22:537-40.
22. Bar-Sagi D, Feramisco JR. Induction of membrane ruf fling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 1986;233:1061-8. (Pubitemid 16032234)
23. Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004;10:1011-22. (Pubitemid 39625245)
24. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013;497:633-7.
25. Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A 2013;110:8882-7.
26. Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res 2013;11:474-81.